CD8A and cancer: These ecto-HSP70 and HSP90 can interact with receptors on the surface APCs (e.g., CD40 and CD91) and enhance the immunogenicity of dying cells, results in the cross-presentation of cancer cell antigens to major histocompatibility complex (MHC)-I molecules and subsequent activation of CD8+ T-cells (16, 25, 26).